We found that patients who were KIR 2D (L1, L3, L4, S4) negative on tumor cells or TILs had longer OS than patients who are KIR 2D (L1, L3, L4, S4) positive on tumor cells (40.70 weeks, 95% CI 24.76-56.65 vs. 7.10 weeks, 95% CI 0.00-19.38, P = 0.014) or TILs (40.70 weeks, 95% CI 24.05-57.35 vs. 3.90 weeks, 95% CI 0.00-9.17, P < 0.001). This evidence concerns the gene KIR3DL1 and neoplasm.